Core Insights - The article discusses the strategic partnership between Wellgistics Health, Inc. and DataVault AI, Inc. to enhance the PharmacyChain platform using advanced technologies [1] - The partnership aims to leverage DataVault AI's edge network and quantum key encryption to improve data-driven outcomes in the $634 billion prescription drug market [1] Company Overview - Wellgistics Health, Inc. is a leader in health information technology, focusing on pharmacy dispensing optimization through its AI platform EinsteinRx [1] - DataVault AI, Inc. specializes in AI-driven data valuation, monetization, and secure tokenization within Web 3.0 environments [1] Technology Integration - The partnership will integrate DataVault AI's advanced technology platform into Wellgistics' PharmacyChain, enhancing its blockchain-enabled smart contracts and tokenization capabilities [1] - Quantum key encryption will fortify pharmacies against potential threats from quantum computing, which could compromise traditional encryption methods [1]

Core Insights - Wellgistics Health, Inc. is integrating its AI platform EinsteinRx into pharmacy point-of-sales systems to enhance prescription drug dispensing efficiency [1] - The company aims to onboard up to 500 pharmacies per month into the Wellgistics Pharmacy Network by the end of 2026 [1] - The focus of the manufacturer-supplier relationship expansion is on diabetes, weight loss, cardiometabolic, and Long COVID patients [1] - Wellgistics is assessing resources for the development of blockchain-enabled smart contracts through its PharmacyChain platform [1] - The company is entering a phase of hyper-focused operational execution under the leadership of President and Interim-CEO Prashant Patel [1]

Core Viewpoint - Wellgistics Health, Inc. is integrating its proprietary AI platform EinsteinRx into its blockchain-enabled smart contracts platform PharmacyChain, enhancing its position in health information technology [1] Group 1: Company Overview - Wellgistics Health, Inc. is a leader in health information technology [1] - The company is publicly traded on NASDAQ under the ticker symbol WGRX [1] Group 2: Product Integration - Wellgistics is combining its AI-driven pharmacy dispensing optimization platform EinsteinRx with its PharmacyChain platform [1] - This integration aims to improve efficiency and effectiveness in pharmacy operations [1] Group 3: Shareholder Information - The company has announced a record date of December 19, 2025, for shareholders to receive Dream Bowl 2026 Meme Coin tokens [1] - Eligible shareholders will receive one Dream Bowl token for each share of common stock owned [1]

Core Insights - Wellgistics Health, Inc. has launched the diabetes prescription drug Brenzavvy® targeting 33 million Americans diagnosed with type II diabetes, primarily through its network of 6,500 independent pharmacies [1][4] - The SGLT-2 inhibitor market, which includes drugs like Jardiance®, reached sales of $16.8 billion in 2024 and is projected to grow to $28.9 billion by 2033, with the U.S. accounting for 40.8% of this market [2][4] - The proprietary EinsteinRx™ artificial intelligence platform will assist pharmacists in optimizing therapy selection and educating providers about Brenzavvy's benefits compared to other SGLT-2 inhibitors [2][3] Company Overview - Wellgistics Health integrates its EinsteinRx™ AI platform with a blockchain-enabled smart contracts platform, PharmacyChain™, to enhance the prescription drug dispensing process [4][5] - The company aims to improve patient access to medications while providing revenue opportunities for pharmacists through patient education on Brenzavvy [3][4] - The launch of Brenzavvy establishes a new model for next-generation drugs that offer specific advantages over established market leaders [4] Market Context - A significant gap exists in the prescription of SGLT-2 inhibitors, with only 11.9% of eligible diabetic patients receiving guideline-recommended prescriptions, indicating a need for improved care [2] - The launch of Brenzavvy is positioned to address the high out-of-pocket costs faced by many patients, particularly those who are uninsured or underinsured [4]

Core Viewpoint - Wellgistics Health, Inc. has announced a record date of December 19, 2025, for shareholders to receive the Dream Bowl 2026 Meme Coin, with one coin distributed for each share owned [1] Company Overview - Wellgistics Health, Inc. is a leader in health information technology, focusing on the implementation of EinsteinRx™ artificial intelligence for prescription drug routing [1] - The company utilizes a blockchain-enabled smart contracts platform, PharmacyChain™, to enhance the reimbursement and dispensing process for prescription medicines [1]

Group 1 - The company plans to distribute Dream Bowl 2026 Meme Coin to shareholders with a record date and distribution date expected in December 2025 [1] - Distribution of the Meme Coin is anticipated to occur in January 2026 [1] - Wellgistics Health, Inc. is involved in the DataVault AI Shareholder Distribution Plan and is sponsoring Dream Bowl 2026 [1] Group 2 - Wellgistics is a leader in health information technology, utilizing EinsteinRx™ artificial intelligence for prescription routing [1] - The company employs PharmacyChain™ blockchain-enabled smart contracts to enhance the tracking and dispensing of prescription drugs [1] - The technology aims to optimize insurance coverage from manufacturers to patients [1]

Core Insights - Wellgistics is positioned to lead in the Web 3.0 Health Information Data Transfer within the $634 billion prescription drug industry through an exclusive licensing agreement with Datavault AI [1][2][6] - The implementation of Wellgistics' EinsteinRx AI hub is expected to optimize automated prescription fulfillment for various stakeholders including manufacturers, pharmacies, and patients [1][4][6] - Datavault's intellectual property enables smart contracts that create a barrier to entry in the $4.9 trillion US healthcare market [1][2] Company Overview - Wellgistics Health, based in Tampa, Florida, specializes in optimizing medication delivery from manufacturers to patients, connecting over 6,500 pharmacies and 200 manufacturers [3][9] - The PharmacyChain initiative aims to digitize the tracking of prescription drugs, ensuring accurate delivery and recommendations for safe use [3][5] Technology and Innovation - The completion of the EinsteinRx AI hub integrates Wellgistics' IT and physical infrastructure, enhancing the efficiency of prescription fulfillment and reducing costs associated with pharmacy benefits managers (PBMs) [4][5][6] - Wellgistics aims to minimize or eliminate PBM rebates, thereby reducing administrative burdens for payers and improving the overall pharmaceutical distribution process [6][7] Market Potential - PwC estimates a $1 trillion opportunity to shift healthcare spending towards a digital-first, proactive, and personalized system [2] - The integration of smart contracts into Wellgistics' operations is expected to significantly improve cost efficiency in the prescription filling process, benefiting various stakeholders in the healthcare ecosystem [6][7]

Financial Results - Wellgistics Health, Inc. reported financial results for the quarter ended September 30, 2025, with a press release issued on November 20, 2025[5]. - The press release includes forward-looking statements regarding the company's projects and potential financial performance[9]. - The press release is attached as Exhibit 99.1, which contains detailed financial results and operational insights[11]. Company Classification and Regulations - The company is classified as an emerging growth company under the Securities Act of 1933[4]. - The company’s Registration Statement on Form S-1 was declared effective by the SEC on September 25, 2025, discussing various risks associated with forward-looking statements[9]. Financial Metrics and Guidance - The company has not yet disclosed specific financial metrics or performance indicators in the provided documents[5]. - The company has not provided specific guidance or outlook for future performance in the available documents[5]. Company Information - The company’s principal executive offices are located in Tampa, FL[1]. - The trading symbol for Wellgistics Health, Inc. is WGRX, listed on The Nasdaq Capital Market LLC[3]. Product and Market Information - The report does not include any information on new products, technologies, market expansion, or acquisitions[5].

Core Viewpoint - Wellgistics Health, Inc. reported its financial results for the period ended September 30, 2025, and provided a business update following the reappointment of Prashant Patel as President and Interim-CEO [1] Financial Results - The financial results were disclosed on Form 10-Q on November 19, 2025, indicating the company's performance metrics for the specified period [1] Business Update - The Interim-CEO highlighted that the last six weeks have provided insights into the various stages of development across different parts of the business since his reappointment on October 6, 2025 [1]

Revenue Generation and Market Overview - Wellgistics Health expects to generate revenues primarily through Wellgistics Pharmacy and Wellgistics LLC after acquiring Wood Sage, LLC in June 2024 and Wellgistics, LLC in August 2024[182]. - The National Health Expenditure Data for 2022 reached $4.5 trillion, accounting for 17.3% of GDP, with an expected increase to 19.7% by 2032[184]. - Total retail prescription drug spending increased by 8.4% from 2021 to 2022, reaching $405.9 billion[184]. - The U.S. market for medicines reached $435 billion in 2023, with the specialty drug market accounting for over 50% of prescription drug spending despite being less than 10% of total drugs[184]. - Wellgistics, LLC serves over 5,000 registered pharmacies nationwide, focusing on competitive pricing and unique products[172]. - Wellgistics Pharmacy is licensed in 32 states and the District of Columbia, expanding its operations to include mail order pharmacy services[178]. - The pharmacy network includes over 19,000 independent pharmacies across the U.S., capable of delivering prescriptions in hours, servicing approximately 1.3 billion prescriptions annually[185]. - Wellgistics Health aims to enhance patient outcomes by improving medication adherence and providing access to clinical resources[185]. - The company plans to expand its wholesale operations and establish new manufacturer relationships to maximize revenues[185]. Financial Performance - Net revenues for the three months ended September 30, 2025, were $3,012,904, a decrease of approximately 47% compared to $5,673,868 for the same period in 2024[198]. - Gross profit for the three months ended September 30, 2025, was $231,012, representing a decline of approximately 56% from $521,244 in 2024[200]. - General and administrative expenses for the three months ended September 30, 2025, increased to $30,172,800 from $1,798,641 in 2024, primarily due to the acquisition of Wellgistics LLC[202]. - Sales and marketing expenses for the three months ended September 30, 2025, were $803,747, compared to $0 for the same period in 2024, reflecting expanded promotional activities[203]. - Net revenues for the nine months ended September 30, 2025, were $21,667,212, compared to $5,718,408 for the same period in 2024, driven by acquisitions[209]. - Gross profit for the nine months ended September 30, 2025, was $1,429,405, an increase of approximately 176% from $518,636 in 2024[211]. - General and administrative expenses for the nine months ended September 30, 2025, were $66,205,669, up from $2,448,813 in 2024, largely due to acquisitions[214]. - Interest expense for the nine months ended September 30, 2025, was $3,703,837, compared to $142,281 in 2024, reflecting increased financing activities[218]. - The significant increase in other expenses for the nine months ended September 30, 2025, totaled $5,024,498, compared to $126,874 in 2024, primarily due to interest expenses and losses related to acquisitions[217]. - The Company recognized a loss of $1,353,663 for the nine months ended September 30, 2025, due to the amendment of the Membership Interest Purchase Agreement, increasing the promissory note from $15 million to $17.5 million[219]. Debt and Financing Activities - As of September 30, 2025, total debt amounted to $24,809,234, an increase from $23,382,901 as of December 31, 2024[225]. - The Company expects to generate positive cash flow from operations in 2025, driven by annual revenue from Wood Sage and Wellgistics LLC[220]. - The Company issued a total of 3,426,254 shares of common stock, resulting in net proceeds of $2,838,787 as of September 30, 2025[223]. - A public offering of 7,142,862 shares of common stock was filed on September 29, 2025, generating net proceeds of approximately $4.53 million[224]. - The Company entered into a secured term loan of $1,300,000 on August 26, 2025, with a total repayment obligation of $1,872,000[231]. - The Company recorded interest expenses of $668,148 for the nine months ended September 30, 2025, related to various debt instruments[230]. - The Company plans to use proceeds from offerings to strengthen working capital, support operations, and pursue strategic acquisitions[224]. - The Company has ongoing initiatives for facility expansion, employee recruitment, and technology upgrades to meet operational needs[221]. - The Company is focusing on strategic acquisitions to enhance its health ecosystem, including investments in artificial intelligence and data warehousing capabilities[222]. - Wellgistics, LLC entered into a new credit agreement for a line of credit of $10,000,000 with an annual interest rate of 16.84%[241]. - As of September 30, 2025, the outstanding balance on the line of credit was $2,973,751, down from $5,531,260 as of December 31, 2024[241]. Cash Flow and Investment Activities - Net cash used in operating activities for the nine months ended September 30, 2025 was $4,561,776, primarily due to a net loss of $72,981,336[247]. - Net cash provided by financing activities for the nine months ended September 30, 2025 was $8,388,250, driven by gross proceeds of $4,000,000 from the IPO and $20,070,000 from the revolving line of credit[250]. - The company fully repaid the $1.2 million promissory note as of September 30, 2025, compared to an outstanding balance of $137,141 as of December 31, 2024[243]. - The company plans to retain future earnings for operations, expansion, and debt repayment, with no current plans to pay cash dividends[245]. - Net cash used in investing activities for the nine months ended September 30, 2025 was $626,144, primarily for capitalized software expenditures[249]. Accounting and Revenue Recognition - The company recognized revenue at the point of sale, with the majority of orders placed via its website[256]. - The company accounts for acquisitions as business combinations, allocating the purchase price to the fair values of acquired assets and liabilities[262]. - As of September 30, 2025, the company had total outstanding debt principal payments of $24,809,234 scheduled through 2028[244].